Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Rheumatology (Oxford, England)
|
November 4, 2020
US rheumatologists' beliefs and knowledge about biosimilars: a survey
Allan Gibofsky, Dorothy McCabe
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 22, 2020
The Importance of Countering Biosimilar Disparagement and Misinformation
Hillel P Cohen, Dorothy McCabe
BMJ Open
|
November 17, 2024
Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials
Vibeke Strand, Dorothy McCabe, Shaun Bender
Rheumatology and Therapy
|
August 9, 2024
Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
Vibeke Strand, Shaun Bender, Dorothy McCabe
Arthritis and Rheumatism
|
November 13, 2002
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial
George Nuki, Barry Bresnihan, Moraye B Bear, et al.
Journal of the American Pharmacists Association : Japha
|
November 27, 2022
Pharmacist biosimilar survey reveals knowledge gaps
James G Stevenson, Dorothy McCabe, Melissa McGrath, et al.
Expert Opinion on Biological Therapy
|
May 13, 2024
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)
Viktoria Moschetti, Susanne Buschke, Julia Bertulis, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 5, 2023
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective
Hillel P Cohen, Matthew Turner, Dorothy McCabe, et al.
Advances in Therapy
|
November 1, 2016
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Hillel Cohen, Donna Beydoun, David Chien, et al.
Journal of Managed Care & Specialty Pharmacy
|
March 29, 2023
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars
Allan Gibofsky, Gary Jacobson, Archie Franklin, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Rheumatology (Oxford, England)
|
November 4, 2020
US rheumatologists' beliefs and knowledge about biosimilars: a survey
Allan Gibofsky, Dorothy McCabe
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 22, 2020
The Importance of Countering Biosimilar Disparagement and Misinformation
Hillel P Cohen, Dorothy McCabe
BMJ Open
|
November 17, 2024
Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials
Vibeke Strand, Dorothy McCabe, Shaun Bender
Rheumatology and Therapy
|
August 9, 2024
Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
Vibeke Strand, Shaun Bender, Dorothy McCabe
Arthritis and Rheumatism
|
November 13, 2002
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial
George Nuki, Barry Bresnihan, Moraye B Bear, et al.
Journal of the American Pharmacists Association : Japha
|
November 27, 2022
Pharmacist biosimilar survey reveals knowledge gaps
James G Stevenson, Dorothy McCabe, Melissa McGrath, et al.
Expert Opinion on Biological Therapy
|
May 13, 2024
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)
Viktoria Moschetti, Susanne Buschke, Julia Bertulis, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 5, 2023
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective
Hillel P Cohen, Matthew Turner, Dorothy McCabe, et al.
Advances in Therapy
|
November 1, 2016
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Hillel Cohen, Donna Beydoun, David Chien, et al.
Journal of Managed Care & Specialty Pharmacy
|
March 29, 2023
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars
Allan Gibofsky, Gary Jacobson, Archie Franklin, et al.
Page
of 2